The Effects of Lipinova on Inflammatory and Proresolving Lipid Mediator Profiles After Orthopedic Surgery

Surgery Clinical Trial

Official title:

The Effects of Dietary Supplementation With Lipinova on Inflammatory and Proresolving Lipid Mediator Profiles in Patients Undergoing Total Knee Arthroplasty

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03434236
• Other study ID #: 2018P000102/PHS
• Status: Not yet recruiting
• Phase: N/A
• First received: February 1, 2018
• Last updated: February 13, 2018
• Start date: March 15, 2018
• Est. completion date: November 1, 2018

Study information

• Verified date: February 2018
• Source: Brigham and Women's Hospital
• Contact: Mieke Soens, MD
• Phone: 617-732-8217
• Email: msoens[@]bwh.harvard.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this pilot study is to investigate whether pre-operative supplementation with an over the counter dietary supplement containing a fractionated marine lipid concentrate derived from anchovy and sardine oil, Lipinova® (Solutex), improves the inflammatory profile and proresolving capacity in patients undergoing total knee arthroplasty. In addition, the investigators will compare the ability of two different dosing regimens to maximize SPM (Specialized Proresolving Mediators) availability.

Description:

The resolution of acute inflammation was once thought to be a passive process, meaning that inflammatory mediators from the acute response (e.g. chemoattractants, complement components, prostaglandins, chemokines and cytokines) would simply dilute and dissipate to stop the infiltration of leucocytes into the tissues. Conversely, more recently it was shown that tissue resolution of inflammation is actually an active programmed process, requiring a temporal lipid mediator class switch that leads to the production of specialized pro-resolving mediators (SPMs) derived from essential fatty acids.1-4

There are several distinct classes of SPMs: the lipoxins derived from the n-6 polyunsaturated fatty acid (n-6 PUFA), AA, and the resolvins, protectins and maresins derived from the n-3 PUFAs, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). These SPMs counter regulate pro-inflammatory mediator production, including prostaglandins, leukotrienes, and select cytokines. They also stimulate leucocyte responses including bacterial phagocytosis and efferocytosis of apoptotic cells, key processes in the clearance of infections and return to homeostasis, without apparent immune suppression.5-7 In addition, Serhan and colleagues8 recently identified a new family of sulfido-conjugated mediators that promote wound repair and tissue regeneration. An increasing body of research has shown the beneficial actions of these mediators on improving the inflammatory process in several disease states, such as sepsis, peritonitis, colitis, Alzheimer's disease and peripheral vascular disease.9-13 In addition, it was demonstrated that RvE1 has direct bone-preserving and bone regeneration functions in a mouse model of periodontal disease.14

There is also increasing evidence suggesting that inflammation has a significant impact on postoperative clinical outcomes. Kimura et al.15 demonstrated that patients who developed postoperative infectious complications after liver resection had significantly higher levels of IL-6 on days 0 and 1 after surgery than did those without infections. In addition, elevated pre-operative CRP-levels in patients undergoing palliative surgery is associated with a higher complication rates and decreased overall survival.16 Pillai et al.17 demonstrated two groups among patients undergoing abdominal aorta aneurysm (AAA) surgery based on their temporal profile: one group displayed a pro-inflammatory profile throughout the intra-operative and postoperative time course, while the other group was characterized by a pro-resolving mediator profile. The authors suggested that these two broad categories may reflect an early resolver population and a delayed resolver population and that enhancing the patient profile of endogenous pro-resolving mediators may shorten recovery times, resolution and improve outcomes in these patients.

In this proposal the investigators aim to determine whether pre-operative dietary supplementation with a nutritional supplement containing omega-3 PUFA and its derivatives will improve the metabolo-lipidomic, inflammatory, and resolution profile of patients undergoing total knee arthroplasty. Lipinova® (Solutex) is an over the counter nutritional supplement that differs from other commercially available "Fish Oil" in that it contains standardized levels of the omega 3- PUFAs, Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) as well as the derived monohydroxylated precursors (17-HDHA, 18-HEPE and 14-HDHA). The standardized levels are obtained from anchovy and sardine oil through advanced fractionation technology and purification technology.

SPECIFIC AIMS:

Specific Aim 1: To characterize the pro-resolving lipid mediator (LM) or specialized pro-resolving mediator (SPM) signature in patients scheduled to undergo total knee arthroplasty. We hypothesize that orthopedic surgery will induce an up-regulation of pro-inflammatory pathways and down-regulation of pro-resolving lipid mediator pathways on postoperative day 1, when compared to pre-operatively.

Specific Aim 2: To determine if pre-operative dietary supplementation with Lipinova®, a purified, fractionated form of fish oil, containing standardized amounts of n-3 essential fatty acids, alters the metabolo-lipidomic profile in patients undergoing total knee arthroplasty. We hypothesize that the oral administration of Lipinova®, which contains precursors for SPMs will upregulate the pro-resolving lipid mediator pathways and down-regulate pro-inflammatory pathways in patients scheduled to undergo total knee arthroplasty, both pre-operatively and on postoperative day 1.

Specific Aim 3: To define a dosing regimen to maximize SPM availability in patients undergoing total knee arthroplasty surgery. We will compare changes in metabolo-lipidomic profiles between patients receiving 2 different doses of Lipinova® supplementation.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 30
• Est. completion date: November 1, 2018
• Est. primary completion date: October 1, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years to 80 Years

Eligibility

Inclusion Criteria:

• Patients scheduled to undergo total knee arthroplasty at Brigham and Women's Hospital

Exclusion Criteria:

• current treatment with corticosteroids or NSAIDs

• evidence of active infection

• chronic liver disease

• end stage renal disease (CKD-5)

• chronic inflammatory disorders

• recent major illness or surgery within 30 days

• use of immunosuppressive medication

• history of organ transplantation

• pregnancy or plans to become pregnant, or lactating

• allergies to fish or fish oil

• coagulation disorders or thrombocytopenia (platelet < 150,000)

Related Conditions & MeSH terms

• Inflammation
• Surgery

Intervention

Dietary Supplement:
• low dose Lipinova (30 mL daily)
Lipinova is a nutritional supplement containing concentrated n-3 PUFA (EPA and DHA) and metabolites
• Placebo
Placebo will have a similar appearance, smell and taste as the nutritional supplement
• high dose Lipinova (60mL)
Lipinova is a nutritional supplement containing concentrated n-3 PUFA (EPA and DHA) and metabolites

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Brigham and Women's Hospital

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	SPM signature profile/Resolution Index	cumulative levels (in pg/mL) in plasma and serum for DHA-derived SPMs (D-series resolvins: RvD1, RvD2, RvD3, RvD4, RvD5, RvD6, 17R-RvD1 and 17R-RvD3), Protectins (PD1, 17R-PD1), Maresins (MaR1) + EPA-derived SPMs (E-series Resolvins (RvE1, RvE2 and RvE3) + n-3 DPA-derived SPM (RvD1 n-3 DPA, RvD2n-3 DPA and RvD5 n-3 DPA), Protectins (10S, 17S-diHDPA), Marins (MaR1 n-3 DPA) and AA-derived Lipoxins (LXA4, LXB4, 15-epi-LXA4 and 15-epi-LXB4). Cumulative levels (in pg/mL) will be compared before and after treatment with supplement/placebo and before and after surgery. Lipid mediator profiling will be done with LC-MSMS.	6 months